Drug Profile
Pixantrone - Servier
Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; PixuvriLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator University of Vermont
- Developer Cell Therapeutics; Neopharm Ltd; Servier
- Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
- Mechanism of Action Alkylating agents; Immunosuppressants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-Hodgkin's lymphoma
- Phase III Diffuse large B cell lymphoma; Follicular lymphoma
- No development reported Cancer
- Discontinued Breast cancer; Myasthenia gravis
Most Recent Events
- 02 Oct 2023 CTI Biopharma withdraws a phase I trial in Cancer (Metastatic disease, Second-line therapy) in USA, prior to enrolment (NCT01632436)
- 05 Oct 2020 CTI BioPharma withdraws a phase III trial prior to enrollment for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00577161) (NCT00551239)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Cancer(In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater, In adults) in USA (IV)